V, S., P, M., V, L., R, M., S, P., B, K., . . . Piemonti, L. (2023). Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: Endo-metabolic features at baseline identify a subgroup of responders. https://doi.org/10.3389/fendo.2023.1175640
Παραπομπή σε μορφή Chicago (17η εκδ.)V, Sordi, et al. Post Hoc Analysis of a Randomized, Double-blind, Prospective Trial Evaluating a CXCR1/2 Inhibitor in New-onset Type 1 Diabetes: Endo-metabolic Features at Baseline Identify a Subgroup of Responders. 2023. https://doi.org/10.3389/fendo.2023.1175640.
Παραπομπή σε μορφή MLA (9th εκδ.)V, Sordi, et al. Post Hoc Analysis of a Randomized, Double-blind, Prospective Trial Evaluating a CXCR1/2 Inhibitor in New-onset Type 1 Diabetes: Endo-metabolic Features at Baseline Identify a Subgroup of Responders. 2023. https://doi.org/10.3389/fendo.2023.1175640.